Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program

Sun Mi Park, Mithat Gönen, Ly Vu, Gerard Minuesa, Patrick Tivnan, Trevor S. Barlowe, James Taggart, Yuheng Lu, Raquel P. Deering, Nir Hacohen, Maria E. Figueroa, Elisabeth M. Paietta, Hugo F. Fernandez, Martin S. Tallman, Ari Melnick, Ross Levine, Christina Leslie, Christopher J. Lengner, Michael G. Kharas

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2- deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)1286-1298
Number of pages13
JournalJournal of Clinical Investigation
Volume125
Issue number3
DOIs
StatePublished - Mar 2 2015

Fingerprint

Leukemia
Stem Cells
Myeloid Leukemia
RNA-Binding Proteins
Survival
Gene Expression Profiling
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Epigenomics
Apoptosis
Messenger RNA
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Park, S. M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T. S., ... Kharas, M. G. (2015). Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program. Journal of Clinical Investigation, 125(3), 1286-1298. https://doi.org/10.1172/JCI78440

Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program. / Park, Sun Mi; Gönen, Mithat; Vu, Ly; Minuesa, Gerard; Tivnan, Patrick; Barlowe, Trevor S.; Taggart, James; Lu, Yuheng; Deering, Raquel P.; Hacohen, Nir; Figueroa, Maria E.; Paietta, Elisabeth M.; Fernandez, Hugo F.; Tallman, Martin S.; Melnick, Ari; Levine, Ross; Leslie, Christina; Lengner, Christopher J.; Kharas, Michael G.

In: Journal of Clinical Investigation, Vol. 125, No. 3, 02.03.2015, p. 1286-1298.

Research output: Contribution to journalArticle

Park, SM, Gönen, M, Vu, L, Minuesa, G, Tivnan, P, Barlowe, TS, Taggart, J, Lu, Y, Deering, RP, Hacohen, N, Figueroa, ME, Paietta, EM, Fernandez, HF, Tallman, MS, Melnick, A, Levine, R, Leslie, C, Lengner, CJ & Kharas, MG 2015, 'Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program', Journal of Clinical Investigation, vol. 125, no. 3, pp. 1286-1298. https://doi.org/10.1172/JCI78440
Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS et al. Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program. Journal of Clinical Investigation. 2015 Mar 2;125(3):1286-1298. https://doi.org/10.1172/JCI78440
Park, Sun Mi ; Gönen, Mithat ; Vu, Ly ; Minuesa, Gerard ; Tivnan, Patrick ; Barlowe, Trevor S. ; Taggart, James ; Lu, Yuheng ; Deering, Raquel P. ; Hacohen, Nir ; Figueroa, Maria E. ; Paietta, Elisabeth M. ; Fernandez, Hugo F. ; Tallman, Martin S. ; Melnick, Ari ; Levine, Ross ; Leslie, Christina ; Lengner, Christopher J. ; Kharas, Michael G. / Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 3. pp. 1286-1298.
@article{f37433df438a477683acd8e4091f4a1c,
title = "Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program",
abstract = "Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2- deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.",
author = "Park, {Sun Mi} and Mithat G{\"o}nen and Ly Vu and Gerard Minuesa and Patrick Tivnan and Barlowe, {Trevor S.} and James Taggart and Yuheng Lu and Deering, {Raquel P.} and Nir Hacohen and Figueroa, {Maria E.} and Paietta, {Elisabeth M.} and Fernandez, {Hugo F.} and Tallman, {Martin S.} and Ari Melnick and Ross Levine and Christina Leslie and Lengner, {Christopher J.} and Kharas, {Michael G.}",
year = "2015",
month = "3",
day = "2",
doi = "10.1172/JCI78440",
language = "English (US)",
volume = "125",
pages = "1286--1298",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Musashi2 sustains the mixed-lineage leukemia'driven stem cell regulatory program

AU - Park, Sun Mi

AU - Gönen, Mithat

AU - Vu, Ly

AU - Minuesa, Gerard

AU - Tivnan, Patrick

AU - Barlowe, Trevor S.

AU - Taggart, James

AU - Lu, Yuheng

AU - Deering, Raquel P.

AU - Hacohen, Nir

AU - Figueroa, Maria E.

AU - Paietta, Elisabeth M.

AU - Fernandez, Hugo F.

AU - Tallman, Martin S.

AU - Melnick, Ari

AU - Levine, Ross

AU - Leslie, Christina

AU - Lengner, Christopher J.

AU - Kharas, Michael G.

PY - 2015/3/2

Y1 - 2015/3/2

N2 - Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2- deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.

AB - Leukemia stem cells (LSCs) are found in most aggressive myeloid diseases and contribute to therapeutic resistance. Leukemia cells exhibit a dysregulated developmental program as the result of genetic and epigenetic alterations. Overexpression of the RNA-binding protein Musashi2 (MSI2) has been previously shown to predict poor survival in leukemia. Here, we demonstrated that conditional deletion of Msi2 in the hematopoietic compartment results in delayed leukemogenesis, reduced disease burden, and a loss of LSC function in a murine leukemia model. Gene expression profiling of these Msi2- deficient animals revealed a loss of the hematopoietic/leukemic stem cell self-renewal program and an increase in the differentiation program. In acute myeloid leukemia patients, the presence of a gene signature that was similar to that observed in Msi2-deficent murine LSCs correlated with improved survival. We determined that MSI2 directly maintains the mixed-lineage leukemia (MLL) self-renewal program by interacting with and retaining efficient translation of Hoxa9, Myc, and Ikzf2 mRNAs. Moreover, depletion of MLL target Ikzf2 in LSCs reduced colony formation, decreased proliferation, and increased apoptosis. Our data provide evidence that MSI2 controls efficient translation of the oncogenic LSC self-renewal program and suggest MSI2 as a potential therapeutic target for myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84924028133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924028133&partnerID=8YFLogxK

U2 - 10.1172/JCI78440

DO - 10.1172/JCI78440

M3 - Article

VL - 125

SP - 1286

EP - 1298

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -